Current strategies for DNA therapy based on lipid nanocarriers

Expert Opinion on Drug Delivery

Volumn 11, Issue 11, 2014, Pages 1721-1731

  Pensado, Andrea ^a   Seijo, Begonã ^a,b   Sanchez, Alejandro ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Santiago University Clinical Hospital   (Spain)

Author keywords

Cationic lipids; Gene therapy; Lipid nanocarriers; Liposomes; Nanoparticles; Nucleic acids; Plasmid DNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; AMPHOPHILE; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CHOLESTEROL; DIOLEOYL PHOSPHATIDYL CHOLINE; DIOLEOYL PHOSPHATIDYLETHANOLAMINE; DNA; GLYCEROL STEARATE; LIPID; LIPID POLYMER HYBRID NANOPARTICLE; LIPOSOME; N [1 (2,3 DIOLEYLOXY)PROPYL] N,N,N TRIMETHYLAMMONIUM CHLORIDE; NANOCARRIER; OLIGONUCLEOTIDE; PLASMID DNA; POLYCATION LIPID NANOCARRIER; POLYMER; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; SORBITAN OLEATE; UNCLASSIFIED DRUG; DRUG; DRUG CARRIER; NANOPARTICLE;

DNA TRANSFECTION; DNA VECTOR; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOGENICITY; LIPOSOMAL GENE DELIVERY SYSTEM; MONONUCLEAR PHAGOCYTE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; REVIEW; STATIC ELECTRICITY; SURFACE CHARGE; SUSTAINED DRUG RELEASE; ANIMAL;

ANIMALS; DRUG CARRIERS; GENETIC THERAPY; HUMANS; LIPIDS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84911490909     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.935337     Document Type: Review

References (70)

1. Peng Z. Current status of gendicine in china: Recombinant human ad-p53 agent for treatment of cancers. Hum Gene Ther 2005;16:1016-27
2. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346-58
3. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011;8:2101-41
4. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev 2009;109:259-302
5. Guo X, Huang L. Recent advances in nonviral vectors for gene delivery. Acc Chem Res 2012;45:971-9
6. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev 2005;57:2106-29
7. Lalatsa A, Schätzlein AG, Mazza M, et al. Amphiphilic poly (l-amino acids)-New materials for drug delivery. J Control Release 2012;161:523-36
8. Safinya CR. Structures of lipid-DNA complexes: supramolecular assembly and gene delivery. Curr Opin Struct Biol 2001;11:440-8
9. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipidmediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-17
10. Zhang S, Xu Y, Wang B, et al. Cationic compounds used in lipoplexes and polyplexes for gene delivery. J Control Release 2004;100:165-80
11. Mosca M, Ceglie A, Ambrosone L. Effect of membrane composition on lipid oxidation in liposomes. Chem Phys Lipids 2011;164:158-65
12. Chen J, Yu Z, Chen H, et al. Transfection efficiency and intracellular fate of polycation liposomes combined with protamine. Biomaterials 2011;32:1412-18
13. Farhood H, Serbina N, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta BBABiomembr 1995;1235:289-95
14. Moghaddam B, McNeil SE, Zheng Q, et al. Exploring the correlation between lipid packaging in lipoplexes and their transfection efficacy. Pharmaceutics 2011;3:848-64
15. Felgner JH, Kumar R, Sridhar CN, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994;269:2550-61
16. Hunt KK, Vorburger SA. Hurdles and hopes for cancer treatment. Science 2002;297:415-16
17. Crook K, Stevenson BJ, Dubouchet M, Porteous DJ. Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum. Gene Ther 1998;5:137-43
18. Zhang Y, Anchordoquy TJ. The role of lipid charge density in the serum stability of cationic lipid/DNA complexes. Biochim Biophys Acta 2004;1663:143-57
19. Bertrand N, Leroux J. The journey of a drug-carrier in the body: an anatomophysiological perspective. J Control Release 2012;161:152-63
20. Aggarwal P, Hall JB, McLeland CB, et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009;61:428-37
21. Zahr AS, Davis CA, Pishko MV. Macrophage uptake of core-shell nanoparticles surface modified with poly (ethylene glycol). Langmuir 2006;22:8178-85
22. Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005;18:209-19
23. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004;269:1-14
24. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994;15:215-20
25. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006;1:297
26. Namiki Y, Fuchigami T, Tada N, et al. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Acc Chem Res 2011;44:1080-93
27. Lasic D, Templeton N. Liposomes in gene therapy. Adv Drug Deliv Rev 1996;20:221-66
28. Igarashi S, Hattori Y, Maitani Y. Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome. J Control Release 2006;112:362-8
29. Woodle MC, Scaria P. Cationic liposomes and nucleic acids. Curr Opin Colloid Interface Sci 2001;6:78-84
30. Igarashi S, Hattori Y, Maitani Y. Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome. J Control Release 2006;112:362-8
31. Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release 2006;116:255-64
32. Zhang Y, Li H, Sun J, et al. DC-chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm 2010;390:198-207
33. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998;5:930-7
34. Mevel M, Kamaly N, Carmona S, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release 2010;143:222-32.
35. Yang S, Zheng Y, Chen J, et al. Comprehensive study of cationic liposomes composed of DC-chol and cholesterol with different mole ratios for gene transfection. Colloids Surf B, Biointerfaces 2013;101:6-13
36. Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipidmediated gene transfer. Gene Ther 1997;4:961-8
37. Chen J, Sun X, Yu Z, et al. Influence of lipid components on gene delivery by polycation liposomes: transfection efficiency, intracellular kinetics and in vivo tumor inhibition. Int J Pharm 2012;422:510-15
38. Endo-Takahashi Y, Negishi Y, Nakamura A, et al. pDNA-loaded bubble liposomes as potential ultrasound imaging and gene delivery agents. Biomaterials 2013;34:2807-13
39. Souto E, Almeida A, Muller R. Lipid nanoparticles (SLN, NLC) for cutaneous drug delivery: structure, protection and skin effects. J Biomed Nanotechnol 2007;3:317-31
40. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN-, NLC-, LDC-) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405
41. Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999;47:125-32
42. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009;71:161-72
43. Kumar S, Randhawa JK. High melting lipid based approach for drug delivery: solid lipid nanoparticles. Mater Sci Eng C Mater Biol Appl 2013;33:1842-52
44. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54(Suppl 1):S131-55
45. del Pozo-Rodŕguez A, Delgado D, Solińs M, et al. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int J Pharm 2007;339:261-8
46. Basaran E, Demirel M, Sirmagül B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010;27:37-47
47. Li X, Nie S, Kong J, et al. A controlledrelease ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008;363:177-82
48. del Pozo-Rodriguez A, Delgado D, Solińs M, et al. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm 2008;360:177-83
49. Del Pozo-Rodŕguez A, Solińs M, Gascón A, Pedraz J. Short-and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm 2009;71:181-9
50. Del Pozo-Rodriguez A, Delgado D, Solinis MA, et al. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int J Pharm 2010;385:157-62.
51. Vighi E, Ruozi B, Montanari M, et al. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int J Pharm 2010;389:254-61
52. Delgado D, Gascón AR, del Pozo-Rodŕguez A, et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm 2012;425:35-43
53. Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 2001;50(Suppl 1):S91-S101
54. Delgado D, del Pozo-Rodŕguez A, Angeles Solińs M, et al. New gene delivery system based on oligochitosan and solid lipid nanoparticles: 'in vitro' and 'in vivo' evaluation. Eur J Pharm Sci 2013;50:484-91
55. Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-16
56. Zorzi GK, Párraga JE, Seijo B, Sánchez A. Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy. Macromol Biosci 2011;11:905-13
57. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009;26:523-80
58. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60
59. Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008;2:1696-702
60. Chan JM, Zhang L, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009;30:1627-34
61. Hoarau D, Delmas P, David S, et al. Novel long-circulating lipid nanocapsules. Pharm Res 2004;21:1783-9
62. Li J, He YZ, Li W, et al. A novel polymer-lipid hybrid nanoparticle for efficient nonviral gene delivery. Acta Pharmacol Sin 2010;31:509-14
63. Zhong Q, Chinta D, Pamujula S, et al. Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes. J Nanobiotechnology 2010;8:6
64. Fang RH, Aryal S, Hu CJ, Zhang L. Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir 2010;26:16958-62
65. Yuan H, Zhang W, Du Y, Hu F. Ternary nanoparticles of anionic lipid nanoparticles/protamine/DNA for gene delivery. Int J Pharm 2010;392:224-31.
66. Zhang Z, Fang X, Hao J, et al. Triolein-based polycation lipid nanocarrier for efficient gene delivery: characteristics and mechanism. Int J Nanomedicine 2011;6:2235-44
67. Sanchez A, Seijo B, Pensado A. Nanoparticles based on sorbitan esters. 2012Available from: http://www. youtube.com/watchv=fda9CtJ5zF0
68. Sanchez A, Seijo B, Zorzi GK, et al. Nanoparticulate systems prepared from sorbitan esters. WO2013068625A1; 2013
69. Pensado A, Seijo B, De La Cerda B, et al. Span nanoparticles as more efficient vectors for in vivo transfection of photoreceptors and RPE cells than adeno-associated viral vectors. Annual Meeting & Exposition of the Controlled Release Society. 13-16 July 2014; Chicago
70. The Journal of Gene Medicine. http://www.wiley.com//legacy/wileychi/genmed/clinical/[Accessed 22 October 2013]